[Click eStock] "Biol, Momentum Overflows... Target Price 13,000 Won"

Yuanta Securities analyzed on the 17th that the momentum for Biol will continue this year. They newly issued a 'Buy' investment rating and a target price of 13,000 KRW.

Yuanta Securities expected Biol to have recorded its highest-ever performance last year. Researcher Son Hyun-jung of Yuanta Securities stated, "Last year's estimated sales and operating profit are 42.3 billion KRW and 22.2 billion KRW, respectively, representing increases of 36.0% and 71.9% compared to the previous year," adding, "This is due to stable sales from increased brand recognition in the U.S. and securing new dealerships in Asia and Europe, including France."

He said, "Consumables sales are expected to be 12.7 billion KRW, accounting for 30.1% of total sales," and added, "Considering that mature medical device companies have a consumables sales ratio of around 50%, Biol has sufficient growth potential."

Additionally, Biol is expected to maintain momentum in the first half of this year. Researcher Son Hyun-jung explained, "This year marks the first year of momentum driven by overseas expansion and new product effects," and noted, "In the fourth quarter of last year, SilfirmX obtained certification in Brazil, and orders are expected to begin in the first quarter of this year, enabling rapid market entry."

He analyzed, "SilfirmX approval is also expected in China during the first half of the year," and added, "The launch of new products HIFU Duotight and non-invasive RF Cellinue is expected to expand the portfolio."

This content was produced with the assistance of AI translation services.